Dr. Zago has served as Prothena’s Chief Scientific Officer since 2017, overseeing the company’s research and drug discovery. He joined Prothena in 2012 when the company was founded, first as Head of Pharmacology and Neuropathology and later as Vice President, Head of Research. Dr. Zago was Principal Scientist at Elan Pharmaceuticals, Inc. While in this position, between 2009 and 2013, he also served as a Scientist at Janssen Alzheimer Immunotherapy. Dr. Zago earned his Ph.D. in Pharmacology at the Universidade de Sao Paulo, Brazil, and was a Post-Doctoral Researcher at the University of California – San Diego and the Burnham Institute.

Zanginyan Hasmik, scientific worker of the Laboratory of Experimental biology of the Institute of Molecular Biology of NAS RA. In 2013, she defended her thesis and received her PhD in Biological Sciences.He is the author of more than 35 works published in various journals and conferences.

I am a principal scientist working at the translational medicine department, Merck Research Laboratories. I was trained as a physician scientist and have 20 years of working experience in discovery and development of positron emission tomography (PET) tracer. I have the expertise to carry out in vitro study of PET tracer biology and pharmacology to support PET tracer development. I have contributed to successful discovery of more than 10 novel central nervous system (CNS) PET tracers at Merck Research Laboratories, including the tau PET tracer, MK-6240. I collaborate with team members and other scientists from different background to drive results. I have contributed to publications on discovery and development of more than 10 novel CNS PET tracers at Merck Research Laboratories, either as a primary investigator or a co-investigator.

Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a Key Member of the Hong Kong Center for Neurodegenerative Diseases and a Visiting Professor in the UW Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin. His main research focus and clinical interest are fluid biomarkers for brain diseases, neurodegenerative diseases in particular.

Dr. Zhang's work focus on oxidant/antioxidant/autophagy. This is evidence by her more than 130 peer-reviewed manuscript regarding how oxidant, antioxidant and autophagy regulation affect neuronal function and survival. Her group developed new concepts that autophagy and mitophagy are essential antioxidant pathways that may provide broad spectrum oxidant and oxidative damage clearance and reversal, as well as novel in vitro and in vivo approaches to assessing mitochondrial function, applying an integrated approach to assess cellular response to oxidative / nitrosative / ER stress, nutrient deprivation, perturbation of glucose metabolism, mitochondrial and environmental toxins, as well as proteotoxicity. Recent studies have begun to identify the integration of multiple stress-sensing pathways, omics, and metabolic/bioenergetic networks in neurodegenerative diseases.

I'm 4th year PhD student in Klenerman group, University of Cambridge. My work focus on the development of single molecule tools for protein aggregates characterisation. Prior to my PhD journey, I was trained as a physicist.

Dr. Zhao is an executive director in the Department of Neuroscience Drug Discovery at Ionis Pharmaceuticals, Inc., a company pioneering in RNA therapeutics. She leads target discovery and validation efforts for Prion Disease, Alzheimer’s and Parkinson’s Disease, and other rare neurogenetic diseases. Dr. Zhao is passionate about her work and impact on patients.